Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: A multicenter, randomized, positive-controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501)

    Journal of Clinical Oncology, 2016.

    Cited by: 0|Bibtex|Views3|

    Abstract:

    TPS8570Background: Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has been recognized as the standard of care in patients with NSCLC harboring sensitive EGFR mutations in advanced stages, their benefits as adjuvant therapy after resection compared with standard platinum-based chemotherapy remained unclear...More

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments